Journal article
Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People
Abstract
Background: Analyses of stored blood from the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) trial identified biomarkers that supplemented clinical risk factors for cardiovascular (CV) events or death. Their performance in participants with diabetes in the Heart Outcomes Prevention Evaluation (HOPE) study and the incremental value of adding high-sensitivity assays of serum troponin I (hsTnI) in the ORIGIN study were assessed.
Authors
Gerstein HC; Paré G; McQueen MJ; Lee SF; Hess S; Investigators FOT
Journal
The Journal of Clinical Endocrinology & Metabolism, Vol. 102, No. 7, pp. 2251–2257
Publisher
The Endocrine Society
Publication Date
July 1, 2017
DOI
10.1210/jc.2017-00273
ISSN
0021-972X